35 results
Thumbnail

D2.207 - Early serum IL-6 induction and delayed IL-17A suppression characterise wasp venom allergen-specific immunotherapy

Thumbnail

D2.196 - Elucidating the Immunological Mechanisms of Pollen Immunotherapy in Treating Food Allergy in Patients with Pollen-Food Allergy Syndrome

Thumbnail

D2.197 - Dose-Dependent Immunogenicity and Toxicity of Polypeptide-Conjugated Hepatitis B Core Antigen Virus‐Like-Particle (HBcAg-VLP) Vaccine for Treatment of Shellfish Allergy

Thumbnail

D2.198 - Allergen identification and characterization of lysine modification in monomeric allergoid of Olea europea pollen extract

Thumbnail

D2.200 - An interim analysis of a multiCenter study on the effect of SCIT on tic symptoms in Children and Adolescents with HDM aLlergy and coMorbid tic disorders (CALM study)

Thumbnail

D2.202 - Evaluation of Telemedicine Use in Dietary Advancement Therapy of Cow’s Milk and Egg Allergy: A Retrospective Study

Thumbnail

D2.204 - Allergic potential of plant-derived oils: in vitro murine model of allergies

Thumbnail

D2.205 - Profilin Allergy: Study of the Efficacy and Safety of an Immunotherapy Protocol for the Treatment of Profilin-Related Oral Allergy Syndrome

Thumbnail

D2.206 - Successful treatment of LTP syndrome using allergen immunotherapy: a clinical case

Thumbnail

D2.209 - 'Which bee was it?': A literature review of Honeybee Venom Immunotherapy used in paediatric patients stung by different bee subspecies

Thumbnail

D2.490 - Consistent efficacy of a seasonal 300IR birch pollen sublingual immunotherapy in children and adolescents during worst pollen exposure: results of the YOBI trial

Thumbnail

D2.491 - Efficacy of a 300IR birch liquid sublingual immunotherapy during the alder and hazel pollen seasons: results of the YOBI trial

Thumbnail

D2.492 - Efficacy and safety of a 300IR daily dose of a SLIT of birch pollen allergen extract in children and adolescents with allergic rhinoconjunctivitis: results from the YOBI trial

Thumbnail

D2.494 - Tralokinumab treatment in adults with atopic dermatitis who were previously treated with dupilumab: 12-months real-world data from the TRACE study

Thumbnail

D2.495 - Treatment with Izicopan (INF904), an oral anti-C5aR inhibitor improves efficacy and safety in patients with chronic spontaneous urticaria: results from a Phase 2a study

Thumbnail

D2.496 - First-in-Human Phase I Clinical Outcomes of BxC-I17e Enriched with HSP70/miR-22-3p in Atopic Dermatitis

Thumbnail

D2.497 - Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Trial

Thumbnail

D2.498 - Berotralstat Decreased HAE Attacks Treated with On-Demand Therapy or Utilizing Professional Care in Pediatric Patients Aged 2 to

Thumbnail

D2.499 - Immunoregulatory Effects of Dupilumab Added to Omalizumab-Facilitated Multi-Allergen Oral Immunotherapy in the COMBINE clinical trial

Thumbnail

D2.503 - LP-003 Injection for the treatment of H1 Antihistamine-Inadequately Controlled Chronic Spontaneous Urticaria (CSU): A Multicenter, Randomized, Double-Blind, Controlled Phase Ⅱ Study